Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Vaccines made from recombinant yeast cells.

Vaccine, 01 Jun 1986, 4(2):75-76
https://doi.org/10.1016/0264-410x(86)90040-x PMID: 3014772 

Abstract 

Production of polypeptide and protein antigens through recombinant DNA technology in prokaryotic and certain eukaryotic cells in culture is facilitating the development of new vaccines that are safe, efficacious, and economically feasible to manufacture. A current example is that of human hepatitis B vaccine that, to the present, has been produced commercially using hepatitis B viral surface antigen (HBsAg) purified from the plasma of human carriers chronically infected with the virus. Production of plasma-derived vaccine is limited by the available supply of suitable carrier plasma and by the need to apply highly technical procedures to purify the antigen as well as to ensure inactivation of all infectious agents that might be present in human plasma.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/0264-410x(86)90040-x

References 

Articles referenced by this article (16)

Show 6 more references (10 of 16)

Citations & impact 

Impact metrics

12
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/58786478
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/58786478

Article citations

Go to all (12) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.